Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 18, 2020 - the FDA announced the approval of Myovant Sciences’ Orgovyx (relugolix), for the treatment of adult patients with advanced prostate cancer.
Return to publications